Breakthrough CBD research

Breakthrough cbd research paves the way towards patient friendly therapies

dsm-firmenich present the first worldwide results comparing their novel CBD formulation CBtru® to Epidiolex.

This Phase I clinical trial shows CBtru® offers equivalent or better bioavailability than the current gold standard, with less variability between subjects and reduced food dependency. This solid formulation breakthrough could transform CBD medication delivery with more convenient dosage options and improved patient experience.

Speaker:

  • Athanasia Kanli - Sr. Director, Global Marketing Pharma, dsm-firmenich

This session lasts 20 min.

hmo webinar screengrab

Related content

Related articles

  • Introducing dsm-firmenich’s new portfolio of taste solutions for pharmaceutical formulations

    Introducing dsm-firmenich’s new portfolio of taste solutions for pharmaceutical formulations

    Discover our novel portfolio offering for the pharmaceutical market, which aims to address a growing need for full-service flavor solutions and taste modulation strategies.

  • New CBD bioavailability study with CBtru®

    New CBD bioavailability study with CBtru®

    New study confirms CBtru®, a novel CBD drug product intermediate, demonstrates equal bioavailability to leading oil-based CBD drug product.

  • Synthetic vs natural CBD ingredients: The differences and why they matter

    Synthetic vs natural CBD ingredients: The differences and why they matter

    Explore five differences between synthetic and natural CBD APIs to inform your next research and development project.

How can we help you?

  • New partnership request

    Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.

  • Sample request

    Don’t just take our word for it. Discover how our solutions can support your product development journey. 

  • Quote request

    Tell us about your project needs. We’ll build you a tailored quote.